1 Prevalence and associated factors of advanced HIV disease

2 among ART-naïve and ART-experienced people with HIV at

3 AHF-supported sites in Zambia

4 Webster Chewe^{1*}, Chitalu Chanda², Benson M. Hamooya³, Lukundo Siame³, Ruth Lindizyani

5 Mfune⁴, Mazinga Kayembe¹, Eric Mpoyi¹, Nduduzo Dube⁵

6

- ⁷ ¹Medical Department, AIDS Healthcare Foundation, Lusaka, Zambia;
- 8 ²Department of Internal Medicine, Ndola Teaching Hospital, Ndola, Zambia
- 9 ³School of Medicine and Health Sciences, Mulungushi University, Livingstone, Zambia
- ⁴Department of Public Health, School of Medicine, The Copperbelt University, Ndola, Zambia

11 ⁵Africa Bureau, A IDS Healthcare Foundation, Manzini, Eswatini

12

13 *<u>webrychew@gmail.com</u> (W.C.)

14

15 Abstract

Background: Individuals with advanced HIV disease (AHD) have a heightened risk of mortality despite access to antiretroviral therapy (ART). Sub-Saharan Africa (SSA) has a disproportionate burden of AHD-associated deaths. However, there is limited country-specific data on AHD's burden and associated risk factors to help design targeted interventions. Therefore, this study determined the prevalence and factors associated with AHD among ART-naïve and ART-

1

It is made available under a CC-BY 4.0 International license .

experienced adults with HIV at five AIDS Healthcare Foundation (AHF)-supported facilities inZambia.

23

Methodology: We conducted a cross-sectional study among 231 ART-naïve and ART-experienced
people living with HIV (PLHIV) and collected demographic and clinical data using a structured
questionnaire. The primary outcome was AHD, defined as a CD4 count less than 200 cells/µL
using the VISITECT® CD4 point-of-care test. Multivariable logistic regression was used to assess
factors associated with AHD.

29

30 *Results:* Among the study participants, 59.7% were female, and 54% were aged 19–35 years. Most 31 participants were ART-naïve (79.2%), with 85.3% classified in WHO clinical stage 1. The 32 prevalence of AHD was 47.6% (110/231), significantly higher among ART-naïve participants 33 [51.9% (95/183)] compared to ART-experienced participants [31.2% (15/48), p=0.011]. ART-34 naïve participants aged 19-35 years exhibited a notably higher prevalence of AHD (51.6%) 35 compared to those aged 13-18, 36-45, and >45 years (5.3%, 34.7%, and 8.4%, respectively) and 36 had significantly higher baseline viral load values (25,000 copies/mL vs. 9,690 copies/mL, p=0.037). Additionally, among ART-naïve participants, a significantly higher proportion of 37 individuals in WHO stages 2, 3, and 4 had AHD compared to those without AHD. Across all 38 participants, the factors significantly associated with AHD included anemia (adjusted odds ratio 39 40 [aOR] 3.03, 95% confidence interval [CI]: 1.15–7.97) and being from the New Masala Clinic 41 health facility (aOR 3.79, 95% CI: 1.17–12.30)

42

It is made available under a CC-BY 4.0 International license .

43	Conclusion: Advanced HIV disease was prevalent, particularly among ART-naïve individuals, and
44	it was significantly associated with anemia and health facility location. There is a need for
45	formulation of interventions, especially among ART-naïve PLHIV who are anemic. Additionally,
46	studies to integrate point-of-care diagnostics such as the VISITECT® CD4 test into routine HIV
47	care be conducted in resource-limited settings are warranted for early detection of AHD.
48	
49	Keywords: AHD, anemia, ART-experienced, ART-naïve, VISITECT® CD4 test, Zambia

50

51 Introduction

Despite over three decades since the onset of the human immunodeficiency virus (HIV) pandemic, 52 53 epidemic control remains elusive. Significant morbidity and mortality persist, particularly among 54 individuals with advanced HIV disease (AHD) [1,2]. According to the World Health Organization 55 (WHO), AHD is defined as CD4 count below 200 cells/µL or WHO clinical stage 3 or 4 [3,4]. The 56 "test and treat" strategy has improved survival rates among people living with HIV (PLHIV), and 57 the rollout of testing in most healthcare facilities has helped reach populations that were previously 58 underserved [5,6]. As a result, treatment coverage has increased across many regions, with several 59 countries reporting that over 95% of PLHIV are on antiretroviral therapy (ART) [7,8]. 60 Furthermore, more than 70% of clients who initiate ART have CD4 counts above 200 cells/µL [9]. 61 However, despite increased efforts in HIV screening and treatment, high mortality among PLHIV 62 remains largely driven by and associated with AHD [10]. AHD is characterized by an increased 63 vulnerability to malignancies and opportunistic infections such as bacterial infections, 64 cryptococcal infections, and mycobacterial diseases like Mycobacterium tuberculosis and

It is made available under a CC-BY 4.0 International license .

nontuberculous mycobacterium [11]. Additionally, AHD is often associated with anemia and
weight loss [2]. Many PLHIV remain asymptomatic due to the natural progression of HIV
infection, which often masks disease progression and leads to late presentation, especially in those
with AHD [12,13].

69 Newly HIV-diagnosed individuals are among the most likely to present with AHD due to low rates 70 of elite HIV control in low- and middle-income countries (LMICs) [14]. Without ART, most 71 PLHIV present with unsuppressed HIV viral loads [15,16]. Furthermore, the risk of AHD is higher 72 among those who are not on ART or have disengaged from care [17,18]. The prevalence of AHD 73 is estimated to be 60% among those who have disengaged from care and 43.2% among ART-naïve 74 PLHIV [19]. While the prevalence of AHD among ART-naïve PLHIV appears to be declining, there is limited trend analysis available for ART-exposed PLHIV who have access to care [20]. 75 76 Approximately 60% of PLHIV on ART still have CD4 counts below 200 cells/µL, and this trend 77 has remained static for years [21]. Disengagement from care continues to be a significant challenge 78 in LMICs [1].

There is limited data on the prevalence and associated factors of AHD among ART-naïve PLHIV and those ART experienced in SSA information cardinal for policy formulation and in informing clinical practice. Therefore, this study aimed to estimate the prevalence and factors associated with AHD among PLHIV who are ART-naïve and ART-experienced in five AIDS Healthcare Foundation (AHF)-supported health facilities in Zambia.

It is made available under a CC-BY 4.0 International license .

84 Methods

85 Study site and study design

A multicenter, cross-sectional study was conducted among individuals with HIV in five health
facilities across Zambia from January 8 to May 31, 2024. The participating sites included AHF
stand-alone ART clinics at Chifundo and Lusungu in Lusaka District, Kapiri Mposhi Urban Clinic
(Kapiri Mposhi District), New Masala Clinic (Ndola District), and Shampande Clinic (Choma
District). These facilities were purposively selected to represent diverse regions across four
provinces of Zambia.

92 Sample size and sampling technique

93 The sample size of 231 participants was determined based on the available testing resources at the 94 selected five facilities during the study period. Purposive sampling was employed to include all 95 patients who met the study's inclusion criteria and were present at the facilities at the time of data 96 collection.

97 Study Definitions

98 Advanced HIV disease (AHD) was defined as any person living with HIV who had a CD4 count

99 of <200 cells/ μ L or was categorized under WHO clinical stage 3 or 4. HIV status was determined

- 100 according to Zambia's national standards [4,22].
- 101 Antiretroviral therapy (ART) status was classified as either ART-naïve or ART-experienced.
- 102 ART-naïve referred to any person living with HIV who had never received ART, while ART-
- 103 experienced referred to those who had previously received or were currently receiving ART.

It is made available under a CC-BY 4.0 International license .

Anaemia was defined as a hemoglobin concentration of less than 13.0 g/dL in males and less than
12.0 g/dL in females [23].

HIV Viral load was defined as a measure of the amount of HIV RNA (viral particles) in a
participant's blood expressed in copies of the virus per milliliter of blood (copies/mL). Suppressed
HIV viral load was defined as a viral load of fewer than 200 copies/mL. Low-level viremia (LLV)
was defined as a viral load between 200 – 999 copies/mL. Unsuppressed HIV viral load was
defined as a viral load of greater or equal to 1,000 copies/mL [24].
Silent transfer was defined as the situation where a person living with HIV presents to a new

healthcare facility with a viral load ≤ 1000 RNA copies/mL, without prior formal documentation

113 or referral from their previous facility [25].

114 Data and sample collection

115 Baseline data were collected using a structured questionnaire developed and administered by 116 trained research assistants. The data included demographic (age and sex) and clinical (ART status, 117 ART regimen, WHO clinical staging, hemoglobin levels, VISITECT® CD4 test, viral load, and 118 urine LAM test) characteristics. Approximately 8 mL of venous blood was collected from each 119 consenting participant into an EDTA tube and stored at room temperature until transported to the 120 designated site laboratory for analysis of hemoglobin levels, CD4 count, and viral load 121 determination. Blood samples were analyzed within 24 hours, and CD4 cell counts were measured 122 using the VISITECT® CD4 test according to the manufacturer's specifications.

It is made available under a CC-BY 4.0 International license .

123 Data analysis plan

124 Data were cleaned in Microsoft Excel and analyzed using STATA 15. Descriptive statistics were 125 used to understand the distribution of variables among the study participants. The Shapiro Wilk 126 test was used to determine the normality of a continuous variable, and since there was no normality, we used the Wilcoxon rank sum test to ascertain a statistical difference between the two medians. 127 128 A relationship between two categorical variables was determined using the Pearson chi-square test 129 or Fisher's exact test, depending on applicability. Multivariable logistic regression was used to 130 ascertain factors associated with AHD. Factors in the final model were selected based on the 131 previous literature. A p-value < 5% was considered statistically significant.

132 Ethics

The study protocol was reviewed and approved by the Tropical Diseases Research Centre (TDRC) ethics review committee (TRC/C4/12/2023) and The National Health Research Authority (NHREB006/29/12/2023). Permission was obtained from the provincial, district, and facility incharges where the study took place. Written informed consent was obtained from study participants. Data were collected without personal identifiers, kept secure and confidential and were applicable, only available to the principal and co-principal investigators.

It is made available under a CC-BY 4.0 International license .

139 **Results**

140 **Basic characteristics of the study participants**

- 141 This study included 231 participants, of whom 59.7% (138/231) were female, and 54% (125/231)
- 142 were in the age group of 19-35 years. Most patients were ART-naïve (79.2%, 183/231), while
- 143 20.8% (48/231) had prior ART experience. The majority of participants (85.3%, 197/231) were
- 144 classified as being in WHO clinical stage 1, and 5.9% (3/51) had positive urine LAM tests.
- 145 Additionally, about one-third of the participants were anemic (33.5%, 77/231).

146 The burden of advanced HIV disease in ART-naïve and ART-

147 experienced Participants

- 148 The overall prevalence of AHD was 47.6% (110/231), higher among ART-naïve participants
- 149 (51.9%, 95/183) than ART-experienced participants (31.2%, 15/48), p=0.011, as shown in Fig 1.

It is made available under a CC-BY 4.0 International license .






Figure 1. Prevalence of Advanced HIV disease and Non-Advanced HIV disease among ARTnaïve and ART-experienced Participants

153 Relationship between AHD and other study variables

154 Among ART-naïve participants with AHD, those in the 19–35 age group had a higher prevalence 155 of AHD (51.6% vs. 5.3%, 34.7%, and 8.4%) and were more likely to be in WHO HIV Clinical Stage 1 (80% vs. 13.7% and 3.2%). ART-naïve individuals with AHD also had significantly higher 156 157 baseline viral load values, 25,000 vs. 9,690, p = 0.037. In the overall analysis (combining ART-158 experienced and ART-naïve participants), those with AHD had higher viral load values at 159 enrolment compared to those without AHD, 26,950 vs. 5,090, p = 0.012. Additionally, anemia was 160 more prevalent in participants with AHD than in those without (41.8% vs. 25.8%, p = 0.010), see 161 Table 1

Table 1: Demographic and Clinical Factors sorted according to advanced HIV disease among ART Experienced and Naïve Participants

	ART-E	xperienced (n=48))	ART	-Naïve (n=183)		Overall (n=231)			
Characteristic Age categories in years* 13-18 19-35	AH	ID		Al	HD	_	Al			
	Yes (n=15)	No (n=33)	<i>p</i> < value	Yes (n=95)	No (n=88)	<i>p</i> -value	Yes (n=110)	No (n=121)	<i>p</i> -value	
			0.482			0.029			0.277	
13- 18	0 (0.0)	3 (9.1)		5 (5.3)	1 (1.1)		5 (4.5)	4 (3.3)		
19- 35	6 (40.0)	8 (24.2)		49 (51.6)	62(70.5)		55 (50.0)	70 (57.9)		
35-45	6 (40.0)	13 (39.4)		33 (34.7)	17 (19.3)		39 (34.5)	30 (34.8)		
> 45	3 (20.0)	9 (27.3)		8 (8.4)	8 (8.4)		11 (10.0)	17 (14.1)		
Sex*			0.367			0.623			0.466	
Male	7 (46.7)	20 (60.6)		56 (59.0)	55 (62.5)		63 (57.3)	75 (62.0)		
Female	8 (53.3)	13 (39.4)		39 (41.1)	33 (37.5)		47 (42.7)	46 (38.0)		
Facility Name*			0.960			0.337			0.502	
Chifundo AHF ART Clinic	3 (20.0)	6 (18.2)		17 (17.9)	24 (27.3)		20 (18.2)	30 (24.8)		
Kapiri Mposhi Urban Clinic	1 (6.7)	3 (9.1)		23 (24.2)	15 (17.1)		24 (21.8)	18 (14.9)		
Lusungu AHF ART Clinic	3 (20.0)	7 (21.2)		17 (17.9)	13 (14.7)		20 (18.2)	20 (16.5)		
New Masala	3 (20.0)	9 (27.3)		22 (23.2)	16 (18.2)		25 (22.7)	25 (20.7)		

Clinic									
Shampande Clinic	5 (33.3)	8 (24.2)		16 (16.8)	20 (22.7)		21 (19.1)	28 (23.1)	
WHO HIV Clinical Staging*			0.587			0.047			0.067
1	11 (73.3)	28 (85.0)		76 (80.0)	82 (93.2)		87 (79.1)	110 (90.9)	
2	2 (13.3)	2 (6.0)		13 (13.7)	4 (4.6)		15 (13.6)	6 (4.9)	
3	2 (13.4)	2 (6.0)		3 (3.2)	2 (2.3)		5 (4.6)	4 (3.3)	
4	0 (0.0)	1 (3.0)		3 (3.2)	0 (0.0)		3 (2.7)	1 (0.8	
Urine LAM Results*						0.692			0.655
Negative				38 (92.7)	2 (100.0)		45 (93.8)	3 (100.0)	
Positive				3 (7.3)	0 (0.0)		3 (6.3)	0 (0.0)	
Viral load at enrolment <i>copies/mL</i> **	45100 (308, 271000)	3830(1190, 54250)	0.223	25000 (7800, 242000)	9690 (40, 2690)	0.037	26950 (7200, 242000	5090 (123, 26800)	0.012
Viral load at enrolment in <i>copies/mL</i> *			0.223			0.26			0.137
< 200	1 (14.3)	4 (20.0)		5 (14.2)	10 (28.6)		6 (14.3)	14 (25.5)	
200- 999	1 (14.3)	0 (0.0)		1 (2.9)	2 (5.7)		2 (4.8)	2 (3.6)	
≥ 1000	5 (71.4)	16 (80.0)		29 (82.9)	23 (65.7)		34 (81.0)	39 (70.9)	
Presence of Anemia*			0.072			0.056			0.010

						I		
	No	8 (53.3)	26 (78.8)	56 (58.9)	63 (72.4)	64 (58.2)	89 (74.2)	
	Yes	7 (46.7)	7 (46.7)	39 (41.1)	24 (27.6)	46 (41.8)	31 (25.8)	
	Abbreviation: AHD: a	edian (interquartile ran dvanced HIV disease; 4	AHF: AIDS Healthcare F				mivudine/Doluteg	ravir;
			amivudine/Dolutegravir; HO: World Health Organ		dine/Efavirenz), TaFED:	l enofovir		
162								
163	Regression Analysis	of Factors Associa	ted with AHD among	g ART-Naïve, ART-I	Experienced, and C	ombined Group Par	rticipants	
164	Table 2 presents the re	esults of bivariable	and multivariable ana	alyses assessing facto	ors associated with A	HD. In the overall c	rude analysis	
165	(combining ART-exp	perienced and ART	-naïve participants),	individuals with ane	mia had 2.06 times	higher odds of bein	ng diagnosed	
166	with AHD compared	to non-anemic indi	viduals (crude odds ra	atio [cOR] = 2.06; 95	5% CI: 1.18–3.60; p	= 0.011). Participant	ts with WHO	
167	clinical stage 2 had 3	.16 times higher of	lds of AHD diagnosi	s compared to those	not in Stage 2 (cOR	= 3.16; 95% CI: 1.	17–8.49; p =	
168	0.022). In the adjusted	d analysis, participa	ints receiving care at	New Masala Clinic h	ad significantly high	her odds of being dia	agnosed with	
169	AHD compared to the	hose from Lusung	ı clinic (adjusted od	ds ratio [aOR] = 3.	79; 95% CI: 1.17–1	2.30; p = 0.027).	Additionally,	
170	participants with aner	nia had 3.03 times	higher odds of receiv	ing an AHD diagnosi	is compared to non-a	anemic participants	(aOR = 3.03;	
171	95% CI: 1.15–7.97; p	0 = 0.024).						
172	In the crude analysis	among ART-naïve	participants, those fr	om Masala clinic we	re 4.67 times more l	ikely to be diagnose	ed with AHD	
173	compared to those from	om Lusungu clinic (cOR = 4.67; 95% CI	: 1.05–20.74; p = 0.0	43). Participants wit	h WHO clinical stag	ge 2 had 3.55	
174	times higher odds of a	AHD diagnosis cor	npared to those in W	HO stage 1 ($cOR = 3$	9.55; 95% CI: 1.10–1	1.38; p = 0.033). In	the adjusted	

175 analysis, participants from New Masala Clinic had significantly higher odds of being diagnosed with AHD compared to those from

176 Lusungu clinic (aOR = 4.67; 95% CI: 1.05–20.73; p = 0.043).

177

	ART-Expe	rienced	(n=48)		ART-Naïve (n=	Overall (n=231)						
years 13 - 18 19 - 35 36 - 45	Crude anal	ysis	Adjusted analysis		Crude analysis		Adjusted analysis		Crude analysis		Adjusted analysis	
	cOR (95% CI)	p- value	aOR (95% CI)	p-value	cOR (95% CI)	p-value	aOR (95% CI)	p-value	cOR (95% CI)	p-value	aOR (95% CI)	p-value
Age categories in years												
13 - 18					5.0 (0.47, 52.96)	0.181	-	-	1.93 (0.42, 8.81)	0.395	9.35 (0.77, 112.6)	0.078
19 - 35	2.25 (0.41, 12.09)	0.34 5			0.77 (0.27, 2.21)	0.663	0.71(0.08, 5.83)	0.755	1.21 (0.52, 2.80)	0.649	1.75 (0.42, 7.21)	0.441
36 - 45	1.38 (0.27,7.04)	0.69 5			1.94 (0.62, 6.08)	0.255	0.87(0.08, 5.83)	0.908	2.00 (0.82, 4.91)	0.127	1.25 (0.28, 5.61)	0.770
> 45	ref				Ref		Ref		Ref		Ref	
Sex												
Male	Ref				Ref		Ref		Ref		Ref	

Table 2. Logistic Regression Analysis of Factors Associated with Advanced HIV Disease among ART Experienced and Naïve Participants

Female	0.57 (0.17, 1.94)	0.36 9	0.84 (0.46, 1.53)	0.582	0.49 (0.12, 1.95)	0.319	0.82 (0.48, 1.39)	0.466	0.68 (0.23, 2.00)	0.487
Facility Name										
Lusungu AHF ART Clinic	Ref		Ref		Ref		Ref		Ref	
Chifundo AHF ART Clinic	1.17 (0.16, 8.09)	0.87 6	0.54 (0.20, 1.40)	0.207	-	-	0.67 (0.28, 1.54)	0.344	-	-
Shampand e Clinic	1.45 (0.25, 8.42)	0.67 3	0.62 (0.23, 1.62)	0.324	-	-	0.75 (0.32, 1.73)	0.502	-	-
Kapiri Mposhi Urban Clinic	0.77 (0.06, 10.86)	0.85 2	1.12 (0.42, 2.98)	0.818	8.82 (0.88, 88.23)	0.064	1.33 (0.56, 3.18)	0.517	3.50 (0.74, 16.67	0.115
New Masala Clinic	0.78 (0.11, 5.10)	0.79 3	1.04 (0.39, 2.76)	0.919	4.67(1.05, 20.74)	0.043	1.00(0.43 , 2.29)	1.00	3.79 (1.17, 12.30)	0.027
Viral load at enrolment in copies/mL										
< 200			Ref		Ref		Ref		Ref	
200 - 999			1.00 (0.07, 13.86)	1.000	0.63 (0 .03, 10.36)	0.749	2.33 (0.26, 20.65)	0.446	2.48 (0.21 28.71)	0.466

			2.43 (0.72, 8.13)	0.148	2.12 (0.39, 11.46)	0.382	2.03 (0.70, 5.88)	0.190	1.91 (0.53, 6.85)	0.317
Ref			Ref		Ref		Ref		Ref	
2.55(0.32, 20.38)	0.37 9		3.55 (1.10, 11.38)	0.033	2.67 (0.30, 23.76)	0.379	3.16 (1.17, 8.49)	0.022	2.97 (0 .58, 15.15)	0.190
			1.64 (0.27, 10.08)	0.593	-	-	1.58 (0.41, 6.06)	0.505	0.07 (0 .003, 1.32)	0.076
			-	-	-	-	3.79 (0.38, 37.10)	0.252	-	-
Ref			Ref		Ref		Ref		Ref	
3.25 (0.87, 12.08)	0.07 9		1.86 (0.99, 3.47)	0.051	2.92 (0.90, 9.46)	0.073	2.06 (1.18, 3.60)	0.011	3.03 (1.15, 7.97)	0.024
	2.55(0.32, 20.38) Ref	2.55(0.32, 20.38) 0.37 9 20.38) 9	2.55(0.32, 20.38) 0.37 9 2.55(0.32, 20.38) 0.37 9 9 1 1	Ref Image: Constraint of the second seco	Ref 8.13) Ref Ref 2.55(0.32, 20.37) 0.37 9 3.55 (1.10, 11.38) 1.64 (0.27, 10.08) 1.64 (0.27, 10.08) 1.008) - Ref <td>Ref Image: Constraint of the second seco</td> <td>Ref Image: Second system 8.13) Image: Image: Second system Image: Image: Second system Ref Image: Image: Second system Ref Image: Second system Ref Image: Second system 2.55(0.32, 20.37) 0.37 Image: Second system Image:</td> <td>8.13) 11.46) 5.88) Ref 11.46) 5.88) Ref 11.46) 5.88) Ref 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46 11.46) 11.46) 11.46 11.46) 11.46 11.46 11.46) 11.46 11.46 11.46 11.46 11.46 11.46 11.46 11.46 11.46 11.46 11.46 11.46 11.46 11.46 1.46 11.46 11.46</td> <td>8.13) 11.46) 5.88) Image: Second system of the system of the</td> <td>1 1 8.13) 11.46) 5.88) 6.85) 1 1 1 11.46) 5.88) 6.85) 1 1 1 1 11.46) 5.88) 6.85) Ref 1 1 1 1 1 1 1 Ref 1 1 1 1 1 1 1 1 2.55(0.32, 20.39) 9.37 1 3.55 (1.10, 11.38) 0.033 2.67 (0.30, 2.376) 0.379 3.16 (1.17, 8.49) 0.022 2.97 (0.58, 15.15) 2.038) 97 1 3.55 (1.10, 10.08) 0.033 2.67 (0.30, 2.376) 0.379 3.16 (1.17, 8.49) 0.022 2.97 (0.58, 15.15) 1.58 0.37 9.7 1.64 (0.27, 10.08) 0.593 - - 1.58 (0.41, 6.06) 0.001 (0.03, 1.32) 1.59 - - - - 1.58 (0.60, 0.03, 1.32) 0.252 - 1.50 - - - - 3.79 (0.38, 37.10) 0.252 - Ref I Ref Ref Ref Ref</td>	Ref Image: Constraint of the second seco	Ref Image: Second system 8.13) Image: Image: Second system Image: Image: Second system Ref Image: Image: Second system Ref Image: Second system Ref Image: Second system 2.55(0.32, 20.37) 0.37 Image: Second system Image:	8.13) 11.46) 5.88) Ref 11.46) 5.88) Ref 11.46) 5.88) Ref 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46) 11.46 11.46) 11.46) 11.46 11.46) 11.46 11.46 11.46) 11.46 11.46 11.46 11.46 11.46 11.46 11.46 11.46 11.46 11.46 11.46 11.46 11.46 11.46 1.46 11.46 11.46	8.13) 11.46) 5.88) Image: Second system of the	1 1 8.13) 11.46) 5.88) 6.85) 1 1 1 11.46) 5.88) 6.85) 1 1 1 1 11.46) 5.88) 6.85) Ref 1 1 1 1 1 1 1 Ref 1 1 1 1 1 1 1 1 2.55(0.32, 20.39) 9.37 1 3.55 (1.10, 11.38) 0.033 2.67 (0.30, 2.376) 0.379 3.16 (1.17, 8.49) 0.022 2.97 (0.58, 15.15) 2.038) 97 1 3.55 (1.10, 10.08) 0.033 2.67 (0.30, 2.376) 0.379 3.16 (1.17, 8.49) 0.022 2.97 (0.58, 15.15) 1.58 0.37 9.7 1.64 (0.27, 10.08) 0.593 - - 1.58 (0.41, 6.06) 0.001 (0.03, 1.32) 1.59 - - - - 1.58 (0.60, 0.03, 1.32) 0.252 - 1.50 - - - - 3.79 (0.38, 37.10) 0.252 - Ref I Ref Ref Ref Ref

Ref: reference group; WHO: World Health Organization

It is made available under a CC-BY 4.0 International license .

179 **Discussion**

180 The overall prevalence of AHD in our study was 47.6%, with a notably higher prevalence among 181 ART-naïve individuals (51.9%) compared to ART-experienced individuals (31.2%). This finding 182 is consistent with studies from other regions, such as South Africa and Sierra Leone, which also 183 highlight the persistent challenge of AHD despite the availability of ART [11,19]. For instance, a 184 study in South Africa reported a higher prevalence of AHD among ART-experienced individuals 185 (58.6%) compared to ART-naïve individuals (43.45%) [19]. Similarly, in Sierra Leone, AHD 186 prevalence was found to be 58.6% among ART-experienced individuals, higher than the 43.5% 187 prevalence among ART-naïve youth aged 15-24 years [11]. These findings from South Africa and Sierra Leone underscore the complexity of AHD management, with ART-experienced individuals 188 189 facing significant challenges despite prolonged ART use [9,11,12,19,26,27]. 190 This high prevalence, particularly among ART-naïve patients, underscores the need for targeted 191 community innovations to ensure that The Joint United Nations Programme on HIV and AIDS 192 (UNAIDS) first 95 target is globally met and that case finding efforts for HIV are comprehensive 193 [28,29]. The significant burden of AHD among both ART-naïve and ART-experienced patients

194 could be due to the lack of targeted HIV case finding, particularly in certain age groups, despite

achieving 95% of patients knowing their HIV status and 95% being on ART [30].

A notable finding of this study was the significant association between anemia and AHD, as observed in both ART-naïve and ART-experienced participants. This association is consistent with existing literature, where anemia is a common comorbidity among PLHIV, particularly those with advanced immunosuppression [31]. The presence of anemia in this population is multifactorial, resulting from chronic inflammation, opportunistic infections, and ART-related toxicities [32,33].

201 The study further found that most participants classified in WHO Stage 1 did not have AHD, which 202 aligns with expected clinical staging outcomes for AHD. In contrast, a higher prevalence of AHD 203 was observed among participants in WHO stages 2, 3, and 4, indicating that advanced clinical 204 staging correlates with the CD4-defined criterion for AHD. This alignment supports the validity 205 of both WHO staging and CD4 counts in identifying individuals with advanced 206 immunosuppression [34–36]. Additionally, the study identified positive results for tuberculosis 207 screening even among participants in WHO Stage 1, suggesting that point-of-care diagnostics like 208 the VISITECT® CD4 test may offer greater sensitivity in detecting AHD. This finding underscores the potential benefit of integrating rapid diagnostic tools into routine clinical practice to improve 209 210 early identification of patients at risk for poor outcomes, thereby supporting more timely 211 interventions.

212 The 19–35-year age group had a higher proportion of AHD among ART-naïve participants. This 213 finding aligns with other studies that have reported a higher prevalence of AHD among youths 214 [11]. The recent Zambia population-based HIV impact assessment (ZAMPHIA) report also 215 highlights the higher incidence of HIV in this age group, coupled with challenges in accessing 216 HIV preventive strategies [30]. These findings may reflect differences in health-seeking behaviors, 217 adherence patterns, or immunological responses among PLWH [37,38]. Therefore, there is a need 218 for tailored interventions targeting specific demographic groups that could help address these 219 disparities.

The study found no significant association between sex and AHD, indicating that both male and female patients are equally at risk of presenting with advanced disease, which could be due to the smaller sample size of our study. This result contrasts with findings from other studies that suggest female sex may be protective [11,26].

17

224 Another noteworthy finding was that 14.3% of both ART-naïve and ART-experienced individuals 225 with a viral load of less than 200 copies/mL presented with AHD. Concurrent AHD and viral load 226 suppression were observed in 14.3% of ART-experienced and 14.1% of ART-naïve patients. This 227 phenomenon may be attributed to "HIV elite control" or "silent transfer," where patients achieve 228 viral suppression despite presenting with AHD [39]. These results were higher than those observed 229 in the Zimbabwe Population-Based HIV Impact Assessment (ZIMPHIA) study, which reported 230 13% of patients with concurrent viral load suppression and AHD [40]. Additionally, low-level 231 viremia, defined as viral loads between 200 and 1000 copies/mL, was associated with AHD, 232 although this association did not reach statistical significance. While the current study did not find 233 a significant association between viral load and AHD, further investigation is warranted into the 234 potential effects of low-level viremia on AHD outcomes. Previous studies have linked low-level 235 viremia to adverse health outcomes, although the association was not statistically significant in the 236 present analysis, possibly due to the small sample size [41].

The significant burden of AHD and the high prevalence of anemia observed in this study
underscore the need for comprehensive care strategies that extend beyond ART provision [42].
Enhancing AHD screening through point-of-care diagnostics, along with further research on the
impact of managing comorbidities like anemia, is essential to improve AHD outcomes.

241 Study limitations and strengths

The study has several limitations. First, the cross-sectional design limits the ability to establish causality between observed factors and AHD. Second, the study relied on a small sample size which may not be representative of the broader population of PLHIV across the country. Third, the use of novel diagnostic methods for AHD, such as the VISITECT® CD4 Advanced Disease

It is made available under a CC-BY 4.0 International license .

Test could lead to variability in prevalence estimates. Despite the limitations, the study was able
to quantify the burden and factors associated with AHD information valuable for informing policy
and clinical practice.

249 Conclusion

250 This study underscores the significant burden of AHD among both ART-naïve and ART-251 experienced participants at selected AHF-supported facilities in Zambia. The high prevalence of 252 AHD, particularly among those newly diagnosed, highlights the ongoing challenges in early HIV 253 diagnosis and the need for targeted intervention, especially considering that the first 95% has been achieved by Zambia. Anemia and health facility location were identified as factors significantly 254 255 associated with AHD. These findings emphasize the urgent need for comprehensive care strategies 256 that integrate routine anemia screening alongside HIV treatment. Additionally, the use of point-257 of-care diagnostics, such as the VISITECT® CD4 test, proved valuable for detecting AHD, 258 particularly in resource-limited settings. The observed prevalence of AHD in patients with 259 suppressed HIV viral loads warrants further investigation, as it may suggest underlying factors 260 such as HIV elite control or "silent transfer". Further exploration into the immunology of elite HIV 261 control and potential vaccine implications is needed.

262 **Funding Statement**

The study was funded by AIDS Healthcare Foundation (AHF). The content of this study is solelythe responsibility of the authors and does not necessarily represent the official views of AHF.

It is made available under a CC-BY 4.0 International license .

265 Authors Contributions

- 266 Conceptualization: W.C., and C.C. Writing (original draft): W.C., C.C., and B.M.H. Writing
- 267 (review and editing): W.C., C.C., B.M.H., L.S., R.L.M., M.K., E.M., and N.D. Visualization: W.C.
- 268 Data collection: W.C., C.C., M.K., and E.M. Data analysis: W.C., C.C., B.M.H, and L.S.
- 269 Supervision: C.C., and E.M. All authors have read and agreed to the published version of the
- 270 manuscript.

271 Conflict of Interest

272 The authors declared no conflict of interest.

273 Acknowledgment

The authors take the opportunity to thank the AIDS Healthcare Foundation Zambia, Zambia Ministry of Health and Management of individual health facilities that enabled us to collect the data for this study.

277 **References**

- 278 1. Meintjes G, Kerkhoff AD, Burton R, Schutz C, Boulle A, Van Wyk G, et al. HIV-Related
- 279 Medical Admissions to a South African District Hospital Remain Frequent Despite Effective
- 280 Antiretroviral Therapy Scale-Up. Medicine (Baltimore) 2015;94:e2269.
- 281 https://doi.org/10.1097/MD.00000000002269 PMID: 26683950
- 282 2. Musengimana G, Umugisha JP, Habinshuti P, Anderson T, Mukesharurema G, Remera E, et

It is made available under a CC-BY 4.0 International license .

- al. Characteristics and clinical outcomes of patients presenting with advanced HIV disease
- in the "treat all" era: a retrospective cohort study from rural Rwanda. BMC Infect Dis
- 285 2022;22:706. <u>https://doi.org/10.1186/s12879-022-07692-w</u> PMID: <u>36008786</u>
- 286 3. World Health Organization. Advanced HIV disease. Geneva: World Health Organization;
- 287 2024. https://www.who.int/teams/global-hiv-hepatitis-and-stis-
- 288 programmes/hiv/treatment/advanced-hiv-
- 289 disease#:~:text=WHO%20defines%20advanced%20HIV%20disease,to%20have%20have%20hav
- 290 <u>ed%20HIV%20disease</u> [cited 2024 Oct 10]
- 291 4. World Health Organization. Guidelines for managing advanced HIV disease and rapid
- initiation of antiretroviral therapy. Geneva: World Health Organization; 2017.

293 <u>https://www.who.int/publications/i/item/9789241550062</u> [cited 2024 Oct 12]

- 5. Girum T, Yasin F, Wasie A, Shumbej T, Bekele F, Zeleke B. The effect of "universal test
- and treat" program on HIV treatment outcomes and patient survival among a cohort of
- adults taking antiretroviral treatment (ART) in low income settings of Gurage zone, South
- 297 Ethiopia. AIDS Res Ther 2020;17:19. <u>https://doi.org/10.1186/s12981-020-00274-3</u> PMID:
- <u>298</u> <u>32423457</u>
- 299 6. Hamooya BM, Mutembo S, Muyunda B, Mweebo K, Kancheya N, Sikazwe L, et al. HIV
- 300 test-and-treat policy improves clinical outcomes in Zambian adults from Southern Province:
- a multicenter retrospective cohort study. Front Public Health 2023;11:1244125.
- 302 <u>https://doi.org/10.3389/fpubh.2023.1244125</u> PMID: <u>37900026</u>
- 303 7. World Health Organization. Despite Remarkable Achievement in Tackling HIV/AIDS,
- 304 Disease Remains 'a Global Crisis, Causing a Death Every Minute', Senior Official Tells
- 305 General Assembly | Meetings Coverage and Press Releases 2023.

It is made available under a CC-BY 4.0 International license .

306 <u>https://press.un.org/en/2023/ga12509.doc.htm</u> [cited 2024 Oct 12]

- 307 8. World Health Organization. New WHO guidance on HIV viral suppression and scientific
- 308 updates released at IAS 2023 2023. <u>https://www.who.int/news/item/23-07-2023-new-who-</u>
- 309 guidance-on-hiv-viral-suppression-and-scientific-updates-released-at-ias-2023 [cited 2024]
- 310 Oct 12]
- 311 9. Mounzer K, Brunet L, Fusco JS, Mcnicholl IR, Diaz Cuervo H, Sension M, et al. Advanced
- 312 HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of
- 313 Recommended 3-Drug Regimens. Open Forum Infect Dis 2022;9:ofac018.
- 314 <u>https://doi.org/10.1093/ofid/ofac018</u> PMID: <u>35169590</u>
- 315 10. Owachi D, Akatukunda P, Nanyanzi DS, Katwesigye R, Wanyina S, Muddu M, et al.
- 316 Mortality and associated factors among people living with HIV admitted at a tertiary-care
- 317 hospital in Uganda: a cross-sectional study. BMC Infect Dis 2024;24:239.
- 318 <u>https://doi.org/10.1186/s12879-024-09112-7</u> PMID: <u>38388345</u>
- 319 11. Baldeh M, Kizito S, Lakoh S, Sesay D, Williams SA, Barrie U, et al. Advanced HIV disease
- and associated factors among young people aged 15—24 years at a tertiary hospital in Sierra
- 321 Leone: a cross-sectional study. BMC Infect Dis 2024;24:611.
- 322 https://doi.org/10.1186/s12879-024-09524-5 PMID: <u>38902606</u>
- 323 12. Jiang H, Liu J, Tan Z, Fu X, Xie Y, Lin K, et al. Prevalence of and factors associated with
- advanced HIV disease among newly diagnosed people living with HIV in Guangdong
- 325 Province, China. J Int AIDS Soc 2020;23:e25642. <u>https://doi.org/10.1002/jia2.25642</u> PMID:
- <u>326</u> <u>33225623</u>
- 327 13. Coul ELMO de, Sighem A van, Brinkman K, Benthem BH van, Ende ME van der,
- 328 Geerlings S, et al. Factors associated with presenting late or with advanced HIV disease in

It is made available under a CC-BY 4.0 International license .

- 329 the Netherlands, 1996–2014: results from a national observational cohort. BMJ Open
- 330 2016;6:e009688. <u>https://doi.org/10.1136/bmjopen-2015-009688</u> PMID: <u>26729389</u>
- 331 14. Okulicz JF, Lambotte O. Epidemiology and clinical characteristics of elite controllers. Curr
- 332 Opin HIV AIDS 2011;6:163. <u>https://doi.org/10.1097/COH.0b013e328344f35e</u> PMID:
- <u>333</u> <u>21502920</u>
- 334 15. Nakalega R, Mukiza N, Debem H, Kiwanuka G, Kakumba RM, Menge R, et al. Linkage to
- intensive adherence counselling among HIV-positive persons on ART with detectable viral
- load in Gomba district, rural Uganda. AIDS Res Ther 2021;18:15.
- 337 <u>https://doi.org/10.1186/s12981-021-00349-9</u> PMID: <u>33879190</u>
- 338 16. Luhembwe M, Ingwe R, Lulebo A, Nkamba D, Ditekemena J. Unsuppressed HIV Viral
- 339 Load and Related Factors in Patients Receiving Antiretroviral Treatment in Tanganyika
- 340 Province, Democratic Republic of Congo (DRC). BioMed 2024;4:338–49.
- 341 <u>https://doi.org/10.3390/biomed4030027</u>
- 342 17. Boyd AT, Oboho I, Paulin H, Ali H, Godfrey C, Date A, et al. Addressing advanced HIV
- disease and mortality in global HIV programming. AIDS Res Ther 2020;17:40.

344 <u>https://doi.org/10.1186/s12981-020-00296-x</u> PMID: <u>32650797</u>

- 18. Mirzazadeh A, Eshun-Wilson I, Thompson RR, Bonyani A, Kahn JG, Baral SD, et al.
- 346 Interventions to reengage people living with HIV who are lost to follow-up from HIV
- treatment programs: A systematic review and meta-analysis. PLOS Med 2022;19:e1003940.
- 348 <u>https://doi.org/10.1371/journal.pmed.1003940</u> PMID: <u>35290369</u>
- 349 19. Kitenge MK, Fatti G, Eshun-Wilson I, Aluko O, Nyasulu P. Prevalence and trends of
- advanced HIV disease among antiretroviral therapy-naïve and antiretroviral therapy-
- 351 experienced patients in South Africa between 2010-2021: a systematic review and meta-

- 352 analysis. BMC Infect Dis 2023;23:549. <u>https://doi.org/10.1186/s12879-023-08521-4</u> PMID:
- 353 <u>37608300</u>
- 20. Trickey A, McGinnis K, Gill MJ, Abgrall S, Berenguer J, Wyen C, et al. Longitudinal trends
- in causes of death among adults with HIV on antiretroviral therapy in Europe and North
- America from 1996 to 2020: a collaboration of cohort studies. Lancet HIV 2024;11:e176–
- 357 85. <u>https://doi.org/10.1016/S2352-3018(23)00272-2</u> PMID: <u>38280393</u>
- 358 21. Auld AF, Shiraishi RW, Oboho I, Ross C, Bateganya M, Pelletier V, et al. Trends in
- 359 Prevalence of Advanced HIV Disease at Antiretroviral Therapy Enrollment 10 Countries,
- 360 2004–2015. Morb Mortal Wkly Rep 2017;66:558–63.
- 361 <u>https://doi.org/10.15585/mmwr.mm6621a3</u> PMID: <u>28570507</u>
- 362 22. Ministry Of Health. Guidelines for Management of Advanced HIV Disease in Zambia.
- **363** 2021.
- 364 23. World Health Organization. Guideline on haemoglobin cutoffs to define anaemia in
- individuals and populations 2024. <u>https://www.who.int/publications/i/item/9789240088542</u>
- 366 [cited 2024 Nov 9]
- 367 24. World Health Organization. The role of HIV viral suppression in improving individual368 health and reducing transmission 2023.
- 369 <u>https://www.who.int/publications/i/item/9789240055179</u> [cited 2024 Nov 10]
- 370 25. World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment,
- 371 service delivery and monitoring: recommendations for a public health approach 2021.
- 372 <u>https://www.who.int/publications/i/item/9789240031593</u> [cited 2024 Nov 10]
- 373 26. Ainembabazi B, Katana E, Bongomin F, Wanduru P, Mayega RW, Mukose AD. Prevalence
- of advanced HIV disease and associated factors among antiretroviral therapy naïve adults

- enrolling in care at public health facilities in Kampala, Uganda. Ther Adv Infect Dis
- 376 2024;11:20499361241251936. <u>https://doi.org/10.1177/20499361241251936</u> PMID:
- **377** <u>38770168</u>
- 378 27. Ik O, Al E, N D, Hn P, M I, E B, et al. Advanced HIV disease in East Africa and Nigeria, in
- The African Cohort Study. J Acquir Immune Defic Syndr 1999 2024;96.
- 380 https://doi.org/10.1097/QAI.0000000003392 PMID: <u>38427929</u>
- 28. UNAIDS. AIDS can be ended by 2030 New UN report. Afr Renew. 2023. Available from:
- 382 https://www.un.org/africarenewal/magazine/july-2023/aids-can-be-ended-2030-new-un-
- **383** <u>report</u> [cited 2024 Nov 11]
- 384 29. UNAIDS. Global AIDS strategy 2021-2026: End inequalities. End AIDS. Geneva:
- 385 UNAIDS; 2021. Available from: <u>https://coilink.org/20.500.12592/pnvx21z</u> [cited 2024 Sep
- 386 10]
- 387 30. Ministry of Health. Zambia Population-based HIV Impact Assessment (ZAMPHIA) 2021.
- 388 2022. Available from: <u>https://www.zamstats.gov.zm/wp-</u>
- 389 <u>content/uploads/2024/01/ZAMPHIA-2021-Final-Report.pdf</u> [cited 2024 Sep 10]
- 390 31. Aemro A, Workneh BS, Mekonen EG, Wassie M, Chekol B. Prevalence of anaemia and its
- 391 associated factors among HIV-infected adults at the time of ART initiation at Debre Markos
- 392 Comprehensive Specialized Hospital, Northwest Ethiopia: a retrospective cross-sectional
- 393 study. BMJ Open 2022;12:e057235. <u>https://doi.org/10.1136/bmjopen-2021-057235</u> PMID:
 394 35725251
- 395 32. Redig AJ, Berliner N. Pathogenesis and clinical implications of HIV-related anemia in 2013.
- 396 Hematology 2013;2013:377–81. <u>https://doi.org/10.1182/asheducation-2013.1.377</u> PMID:
- 397 24319207

- 398 33. Opie J, Verburgh E, Bailly J, Mayne E, Louw V. Hematological Complications of Human
- 399 Immunodeficiency Virus (HIV) Infection: An Update From an HIV-Endemic Setting. Open
- 400 Forum Infect Dis 2024;11:ofae162. <u>https://doi.org/10.1093/ofid/ofae162</u> PMID: <u>38601746</u>
- 401 34. Aregay AD, Kidane KM, Aregay AB, Fenta KA, Woldegebriel AG, Godefay H, et al.
- 402 Prediction of CD4 T-Lymphocyte Count Using WHO Clinical Staging among ART-Naïve
- 403 HIV-Infected Adolescents and Adults in Northern Ethiopia: A Retrospective Study. AIDS
- 404 Res Treat 2020;2020:2163486. <u>https://doi.org/10.1155/2020/2163486</u> PMID: <u>32411452</u>
- 405 35. Munthali C, Taegtmeyer M, Garner PG, Lalloo DG, Squire SB, Corbett EL, et al. Diagnostic
- 406 accuracy of the WHO clinical staging system for defining eligibility for ART in sub-Saharan
- 407 Africa: a systematic review and meta-analysis. J Int AIDS Soc 2014;17:18932.
- 408 https://doi.org/10.7448/IAS.17.1.18932 PMID: 24929097
- 409 36. Kaplan SR, Oosthuizen C, Stinson K, Little F, Euvrard J, Schomaker M, et al.
- 410 Contemporary disengagement from antiretroviral therapy in Khayelitsha, South Africa: A
- 411 cohort study. PLOS Med 2017;14:e1002407. <u>https://doi.org/10.1371/journal.pmed.1002407</u>
- 412 PMID: <u>29112692</u>
- 413 37. Audi C, Jahanpour O, Antelman G, Guay L, Rutaihwa M, van de Ven R, et al. Facilitators
- 414 and barriers to antiretroviral therapy adherence among HIV-positive adolescents living in
- 415 Tanzania. BMC Public Health 2021;21:2274. <u>https://doi.org/10.1186/s12889-021-12323-1</u>
- 416 PMID: <u>34903209</u>
- 417 38. Society for Adolescent Health and Medicine. Improving Outcomes for Adolescents and
- 418 Young Adults Living With HIV. J Adolesc Health. 2023;73:605–9.
- 419 https://doi.org/10.1016/j.jadohealth.2023.05.006 PMID: <u>37422741</u>
- 420 39. Boufassa F, Lechenadec J, Meyer L, Costagliola D, Hunt PW, Pereyra F, et al. Blunted

- 421 Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International
- 422 HIV Controller Collaboration. PLOS ONE 2014;9:e85516.
- 423 https://doi.org/10.1371/journal.pone.0085516 PMID: 24465584
- 424 40. Balachandra S, Rogers JH, Ruangtragool L, Radin E, Musuka G, Oboho I, et al. Concurrent
- 425 advanced HIV disease and viral load suppression in a high-burden setting: Findings from the
- 426 2015–6 ZIMPHIA survey. PLoS ONE 2020;15:e0230205.
- 427 https://doi.org/10.1371/journal.pone.0230205 PMID: <u>32584821</u>
- 428 41. Elvstam O, Marrone G, Medstrand P, Treutiger CJ, Sönnerborg A, Gisslén M, et al. All-
- 429 Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human
- 430 Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results
- 431 From a Swedish Nationwide Observational Study. Clin Infect Dis Off Publ Infect Dis Soc
- 432 Am 2020;72:2079–86. <u>https://doi.org/10.1093/cid/ciaa413</u> PMID: <u>32271361</u>
- 433 42. Kamvuma K, Masenga S, Hamooya B, Chanda W, Munsaka S. Prevalence and factors
- 434 associated with moderate-to-severe anaemia among virally suppressed people with HIV at a
- 435 tertiary hospital in Zambia. PLOS ONE 2024;19:e0303734.
- 436 <u>https://doi.org/10.1371/journal.pone.0303734</u> PMID: <u>39186572</u>